DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Plinabulin is an investigational drug.
There have been 8 clinical trials for Plinabulin. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Neutropenia, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are BeyondSpring Pharmaceuticals Inc., National Cancer Institute (NCI), and Lyudmila Bazhenova, M.D.
There are fifteen US patents protecting this investigational drug and ninety-one international patents.
Recent Clinical Trials for Plinabulin
|A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer||Jyoti Malhotra||Phase 1/Phase 2|
|Plinabulin iv Solution in Prevention of TAC Induced Neutropenia||BeyondSpring Pharmaceuticals Inc.||Phase 2|
|Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)||BeyondSpring Pharmaceuticals Inc.||Phase 2/Phase 3|
Top disease conditions for Plinabulin
Top clinical trial sponsors for Plinabulin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Plinabulin||Start Trial||Method of treating a brain tumor||BeyondSpring Pharmaceuticals, Inc. (New York, NY)||Start Trial|
|Plinabulin||Start Trial||Plinabulin compositions||BeyondSpring Pharmaceuticals, Inc. (New York, NY)||Start Trial|
|Plinabulin||Start Trial||Method of treating cancer associated with a RAS mutation||BeyondSpring Pharmaceuticals, Inc. (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|